This case illustrates that isolated <i>PIK3CA</i>-mutant NSCLC can be highly refractory to conventional chemoimmunotherapy, including regimens incorporating a cytotoxic T-lymphocyte-associated antigen 4 inhibitor. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.